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The human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) is transactivated by various
extracellular signals and viral cofactors that include human herpesviruses. These transactivators are capable
of transactivating the HIV-1 LTR through the transactivation response element, NF-KB, or other regulatory
binding elements. Human herpesvirus 6 (HHV-6) is a potential cofactor of HIV-1. Here, we report that an
HHV-6 gene segment, ZVH14, which can neoplastically transform NIH 3T3 and human keratinocytes, is
capable of transactivating HIV-1 LTR chloramphenicol acetyltransferase constructs in an Spl binding
site-dependent manner. Transactivation increased synergistically in the presence of multiple Spl sites and was
dramatically reduced by cotransfection with oligomers designed to form triplex structures with HIV-1 LTR Spl
binding sites. HIV-1 LTR NF-KB sites were not essential for ZVH14-mediated transactivation. A putative open
reading frame in ZVH14, B115, which may encode a highly basic peptide consisting of 115 amino acid residues,
showed transactivation capacity similar to that of ZVH14. This open reading frame also transactivated the
HIV-1 LTR in an Spl site-dependent fashion in African green monkey kidney cells and human T cells. These
data suggest that HHV-6 may stimulate HIV-1 replication via transactivation of Spl binding sites present in
the HIV-1 promoter.
Human immunodeficiency virus type 1 (HIV-1) is the widely
accepted etiologic agent for AIDS. Gradual depletion of
immune regulatory T cells and apoptosis (programmed cell
death) may occur by direct effects of cytopathic HIV variants
that may contribute to the attenuation and collapse of the
immune system. The mechanism of cell depletion may include
gpl20 binding to CD4 (29) and the upregulated release of
cytokines such as tumor necrosis factor alpha or transforming
growth factor beta (39). Virus expression can be enhanced by
activation with cofactors such as CD3 antibodies (29) or by
activation of HIV long terminal repeat (LTR)-directed viral
gene expression by exogenous viral infection, such as by herpes
simplex virus (13, 30, 31, 34), human cytomegalovirus (3, 5, 8),
human hepatitis B virus (41), and human herpesvirus 6
(HHV-6) (9). Among them, HHV-6 may play a prominant role
because HHV-6 and HIV-1 are similar in CD4+ cell tropism.
HHV-6 was first isolated from the peripheral blood mono-
nuclear cells of six adult patients from the United States and
Jamaica who had lymphoproliferative diseases and AIDS (40,
43). The virus has also been isolated from infants with exan-
them subitum (1, 42) and from patients with various other
diseases. The virus is identified as the etiologic agent of
exanthem subitum (42). HHV-6 infects many of the same cell
types as HIV-1 does (26), and coinfection of T lymphocytes
with HIV-1 and HHV-6 leads to accelerated cytopathic effects
(26). Infection of CD8+ cells by HHV-6 induces surface
expression of CD4, rendering them susceptible to infection
* Corresponding author. Mailing address: Division of Viral Prod-
ucts, CBER, FDA, 8800 Rockville Pike 29A/lA21, Bethesda, MD
20892. Phone: (301) 496-4330. Fax: (301) 496-1810.
with HIV-1 (27). The HIV-1 LTR is activated in HHV-6-
infected primary human T lymphocytes (9) and T-cell lines
(18) and leads to increased HIV-1 gene expression and virus
replication. This activation is via nuclear factors binding to the
HIV-1 LTR enhancer (9). These observations suggest that
HHV-6 may be an important cofactor in HIV-1 infection and
may contribute to the progression of AIDS. However, other
reports show that HHV-6 can suppress HIV-1 infection in vitro
(6, 23).
Previous studies conducted by Razzaque et al. (37, 38) have
demonstrated that a genomic fragment, ZVH14, of HHV-6
strain GS can neoplastically transform NIH 3T3 and human
keratinocyte cells. Horvat et al. (19) have shown that the same
fragment can transactivate the HIV-1 LTR in primary lympho-
cytes. In this study, we provide evidence that the HHV-6
ZVH14 gene segment transactivates the HIV-1 LTR predom-
inantly through Spl binding sites. Within ZVH14, a fragment
containing a small open reading frame (ORF) retains the
capacity to transactivate the HIV LTR.
MATERIALS AND METHODS
Cells. The African green monkey kidney cell line CV1
(ATCC CCL 70) was routinely maintained in Dulbecco's
modified Eagle's medium (DMEM). The human T-cell line H9
(ATCC HTB 176) was maintained in RPMI 1640 medium.
Both media were supplemented with 10% fetal calf serum
(GIBCO BRL), 100 U of penicillin G per ml, 100 jig of
streptomycin per ml, and 2 mM L-glutamine. Cells were fed
twice weekly and split at ratios of 1:5 to 1:10 as needed.
Plasmids. Plasmid pZVH14 (8.7-kb HindIll fragment in
pBS vector) of HHV-6 strain GS was generated as described
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FIG. 1. Determination of the elements necessary for transactivation by pZVH 14. (A) CAT reporter constructs used in cotransfection assays.
(B) Relative CAT activities of constructs used in cotransfection of CV1 cells with pZVH14. CV1 cells were transfected with 1 .g of different
deletion constructs of the HIV-1 LTR CAT expression vector with or without pZVH14 by the calcium phosphate method. Conversion of
chloramphenicol to acetylated forms was calculated by scintillation counting after thin-layer chromatography as described previously (2). The data
are representative of four independent experiments.
previously (22). Subclones pZVH14-1, pZVH14-2, pZVH14-3,
pZVH14-5, pZVH14-6, pZVH14-7, pZVH14-8, and
pZVH14-A were constructed by digestion of pZVH14 with
SmaI, PstI, ClaI, HincII, SmaI-EcoRV, MluI, NsiI, and AccI,
respectively, and self-ligated by T4 DNA ligase. Plasmid
pZVH14-4 was constructed by ligation of pZVH14 partially
digested with XbaI. Plasmid pZVH14-12 was constructed by
inserting the 0.8-kb PstI-HindIII segment of pZVH14 into PstI-
and HindIll-digested pBS vector. pZVH14-10 and pZVH14-11
were constructed by digesting pZVH14-1 first with Hindlll
then with EcoRV and MluI respectively, filling in the ends with
DNA polymerase fragment, and then ligating the ends with T4
DNA ligase. All clones have been confirmed by restriction
enzyme analysis. The intact HIV LTR chloramphenicol acetyl-
transferase (CAT) - 57CAT, and - 29CAT constructs were
gifts from Charles Wood. - 83CAT and - 69CAT were con-
structed in the laboratory. - 117Sp3CAT, - 117Sp3/2CAT,
-117Sp3/ICAT, and - 117CAT were described previously
(46). Plasmid DNAs used in transfections were purified by the
alkaline lysis method followed by double CsCI-ethidium bro-
mide density gradients. After dialysis, the plasmid DNAs were
precipitated with ethanol and redissolved in sterile water.
Concentrations were calculated from A260 determinations and
checked on agarose gels.
Synthesis of oligonucleotides. Oligonucleotides were synthe-
sized on a model 8700 nucleic acid synthesizer (Millipore) by
the H phosphoramidite method. After synthesis, oligonucleo-
tides were purified by C18 high-pressure liquid chromatogra-
phy (Waters). For cellular studies, the oligonucleotides were
further purified on an 8% denaturing polyacrylamide gel,
electroeluted into dialysis tubes, desalted by using NAP-25
chromatography (Pharmacia LKB), ethanol precipitated, and
resuspended in distilled sterile water.
Transfection. Transfections of CV1 cells were performed by
the calcium phosphate-DNA coprecipitation technique (15).
Precipitates were added to cells that had been plated 48 h
before at a density of 3 x 105 to 5 x 105 cells per 100-mm-
diameter dish. For most transfections, 1 pg of CAT plasmid
was coprecipitated with effector plasmids and calf thymus
DNA (to adjust the total DNA to 30 ,ug). Precipitates were left
on the cells overnight (16 h), and then the monolayers were
subjected to a 2-min 15% glycerol-DMEM shock. After being
washed in phosphate-buffered saline, the cells were fed with 10
ml of DMEM containing 10% fetal bovine serum. Cells were
harvested 48 h later for CAT enzyme activity analysis (2). Each
transfection was performed a minimum of two times in dupli-
cate, with the contents of the two plates pooled at the time of
cell harvest. Transfections of H9 cells were carried out by the
DEAE-dextran method (25).
CAT assay. CAT assays were carried out as described by
Gorman et al. (14), and the percentage of acetylation and fold
induction were determined as described previously (2).
Expression vectors. Two putative ORFs, RF2 and RF5, of
pZVH14 were amplified by PCR with the following tempera-
ture profile: 96°C, 20 s; 55°C, 20 s; and 72°C, 30 s (total of 20
cycles). The PCR products were purified by miniprep spun
column chromatography (Pharmacia LKB) and codigested
with pSV-SPORT 1 expression vector (GIBCO BRL), which is
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FIG. 2. Determination of the critical role of Spl sites in transacti-
vation of the HIV LTR by pZVH14 in the presence of NF-KB sites.
(A) CAT reporter constructs used in cotransfection assays. (B) Rela-
tive CAT activities of constructs used in cotransfection of CV1 cells
with pZVH14. The data are representative of at least three indepen-
dent experiments.
driven by the simian virus 40 early promoter, and ligated by T4
DNA ligase. Clones were screened by the colony hybridization
method described by Hanahan and Meselson (17) and con-
firmed by restriction analysis and sequencing.
DNA sequencing and sequence analysis. DNA sequencing
was conducted by using a Sequenase version 2.0 kit (United
States Biochemical) as specified by the manufacturer. Se-
quences were analyzed by the method of Pearson and Lipman
(35) on an NIH Convex system.
RESULTS
Transactivation of the HIV LTR by the HHV-6 genomic
fragment in pZVH14 is not just T-cell specific. The HIV LTR
can be transactivated by HHV-6 infection in human T-cell lines
and in primary human T cells (18, 19). The 8.7-kb ZVH14
genomic segment of HHV-6 (GS) able to transactivate the
HIV LTR when cotransfected into human T cells (19). To
determine whether HIV-1 LTR transactivation by pZVH14 is
cell type specific, CV1 cells were used in transfection. CV1
cells have been used to study transactivation of the HIV LTR
with various cofactors. Cotransfection of the HIV LTR CAT
construct with pZVH14 resulted in a more than 10-fold
increase in CAT enzymatic activity (Fig. 1). Consistent with
previous report by Horvat et al. (19), the pZVB70 fragment
had stronger activity than pZVH14 (data not shown). Our data
Effector: pZVH14(jig) 0 4 8 4 8 4 8 4 8
Competitor: HIVlSp
HIVlSpC
HIV1 NF-B --+ +
FIG. 3. Inhibition of pZVH14-induced transactivation of the
HIV-1 LTR by cotransfection with oligomers designed to form triplex
DNA with three Spl binding sites. (A) Sequence of the HIV-1 LTR.
The sequences of oligomers are shown under the duplex target
sequence. (B) Representative thin-layer chromatography of [ 14C]
chloramphenicol and its acetylated products showing the effects of
different oligomers in ZVH14-induced transactivation. One micro-
gram of HIV-1 LTR CAT and 4 ,ug (lanes 2, 4, 6, and 8) or 8 ,ug (lanes
3, 5, 7, and 9) of pZVH14 were cotransfected with 1 pg of each
oligomer into CV1 cells. The data were reproduced in three indepen-
dent experiments.
show that HHV-6 (GS) genomic fragment ZVH14 can also
transactivate the HIV LTR in CV1 cells.
Role of NF-KB and Spl binding sites in pZVH14-induced
transactivation of the HIV LTR. It has been reported that
HHV-6 increases HIV-1 expression in coinfected T cells via
nuclear factors binding to the HIV-1 enhancer (9) and that
NF-KB sites are required for another HHV-6 22-kb genomic
subclone, pZVB70, to transactivate the HIV LTR (11, 19). To
map the elements required for transactivation by pZVH14, a
series of HIV LTR deletion constructs containing from one to
three Spl sites but without NF-KB sites was tested for response
to pZVH14. Deletion of NF-KB enhancer elements did not
cause a large reduction of basal-level promoter activity (Fig. 1).
These elements were not required for transactivation, as shown
by cotransfection of pZVH14 with the - 83CAT construct
(containing three Spl sites, a TATA box, and a transactivation
response element [TAR]), in which case CAT activity was
elevated 11-fold. This result is consistent with a previous report
showing that pZVH14 can transactivate the HIV-1 LTR even
with NF-KB sites mutated (19).
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FIG. 4. Schematic outline of deletion and truncation clones of pZVH14 and their CAT activities. The entire insert of pZVH14 is schematically
depicted with the restriction sites used in cloning. CV1 cells were cotransfected with 1 jig of the HIV-1 LTR CAT expression vector and 8 ,ug of
a pBS or pZVH14 subclone; 50 ,ul of a 200-,u extract (from two duplicate dishes) was used for measuring CAT activity after incubation for 30 min.
Values represent averages of two assays.
Using constructs varying in number of Spl sites, we found
that pZVH14 activated transcription at a moderate level
(threefold) from - 57CAT containing Spl site I, as determined
by liquid scintillation counting (Fig. 1). This activation was
more than eightfold with - 69CAT, which contains two Spl
sites (I and II). The presence of the third Spl site (site III) in
-83CAT further enhanced the basal-level transcription, and
transactivation was elevated up to 11-fold. No elevated CAT
activity was observed in the -29CAT construct, which con-
tains the TATA and TAR elements with all three Spl binding
sites being deleted. The data presented here indicate that for
efficient transactivation, more than one Spl site is required,
which is consistent with the reports of Jones et al. (20).
To confirm this finding, constructs containing the two
NF-KB sites and the TATA and TAR sites with variable
numbers of Spl sites were used (Fig. 2). Internal deletion of all
three Spl sites with the presence of NF-KB, TATA, and TAR
sites (- 117SP3/1) caused the complete loss of transactivation
by pZVH14, while this construct can still be transactivated by
tax and tat (46). This finding indicates that even at low basal
activity of an Spl-less construct, transactivation is possible, and
pZVH14 failed to transactivate it because of the absence of
Spl sites. With the presence of NF-KB, Spl site I, TATA, and
TAR (- 117SP3/2), subtle levels of transactivation were ob-
served. With the presence of NF-KB, Spl sites I and II, TATA,
and TAR (- 117SP3), enhanced activation was observed.
These studies indicated that Spl binding sites are essential and
that maximal stimulation of the HIV LTR by pZVH14 re-
quires Spl sites I and II.
Inhibition of pZVH14-elevated transcription of the HIV-1
LTR by oligomers designed to form a triplex with Spl binding
sites. Several studies have demonstrated that oligomers can
inhibit promoter activities through formation of triplex with
certain elements of promoters. The formation of a triplex
DNA molecule (forming a T:AT triplet or C+:GC triplet)
occurs through the binding of polypurine oligonucleotides to a
polypurine/polypyrimidine site in a sequence-specific manner
(32). It has also been demonstrated that the presence of strictly
polypurine/polypyrimidine DNA sequences is not absolutely
necessary for the formation of triplex DNA (4, 45). A non
strictly polypyrimidine:polypurine/polypyrimidine site can
form a triplex which can also functionally inhibit transcription
in vitro and in vivo (4, 7, 10, 33, 44, 45). Although the sequence
of the Spl binding site of the HIV LTR is not purely
polypurine/polypyrimidine, it has been demonstrated that it
may form triplex DNA under certain conditions and suppress
viral replication by inhibiting transcription and transactivation
(28). In this experiment, three oligomers, HIVSp, HIVSpC,
and HIV NF-KB, were designed. HIVSp is the parallel form of
HIV LTR -46 to -79 with substitutions of A to T and C to
G. HIV NF-KB is the parallel form of HIV LTR -82 to - 103
with substitutions of A to T and C to G. HIVSpC has the same
base composition as HIVSp but contains designated point
mutations with respect to HIVSp. To test whether these
oligomers can inhibit pZVH14-induced transactivation of the
HIV LTR, they were cotransfected with HIV LTR CAT and
pZVH14 into CV1 cells, and CAT activity was measured. As
illustrated in Fig. 3, the activity of the HIV LTR was signifi-
cantly ("90% by liquid scintillation counting) inhibited when
cotransfected with HIVSp, as expected. HIVSp also substan-
tially inhibited the basal LTR transcription. Although suppres-
sion was observed with HIVSpC, the level of suppression was
much lower than that of HIVSp. No inhibition was observed
with the treatment of HIV NF-KB oligomers. We also found
that the triplex oligomers (HIVSp and HIVSpC) failed to
inhibit transcription from the Rous sarcoma virus LTR and the
VOL. 68, 1994
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localized the major transactivating domain of pZVH14 to a
1.7 8.8 0.6 5.3 1-kb HincII-XbaI fragment.
Lngey)wB115 is as strong as ZVH14 in transactivation of the HIV-1
L6 ^ N XLTR. Three putative ORFs, RF1, P399, and BI 15, are present
in the 2.8-kb HindIII-XbaI fragment (Fig. 5). B115, encoding
115 amino acid residues, was amplified by PCR and cloned into
pSV-SPORT 1 (GIBCO BRL) under the control of simian
virus 40 early promoter. The resulting plasmid was designated
pSV-B1 15. Similarly, P399, encoding 399 amino acid residues,
* w % g | X _ was cloned and designated pSV-P399. A subclone, pZVH14-A,
which maintains the entire RF1 and B1 15 with disrupted P399,
was also constructed as described in Materials and Methods.
pSV-P399, pSV-BI15, pZVH14-A, or pZVH14-5 (in which
+ + + + only RF1 is complete) was cotransfected along with HIV-1
iV-P399 pSV-B115 pZVH14-5 pZVH14-A LTR CAT into CV1 cells. Both pSV-B115 and pZVH14-A
containing B115 showed transactivating potential similar to
e of the three left-hand subclones of that of pZVH14 (Fig. 5), but pSV-P399 and pZVH14-5
ors, pSVB115 and pSVP399, with the showed little or no effect. The sequence of BI 15 was obtained
tp are displayed, and all three ORFs from GenBank (accession number S57540) as part of pZVH14
ows show the locations of restriction (21) and confirmed by us after PCR amplification and cloning
I fragment. RF1, P399, and B115 are into pSV-SPORT 1. The DNA sequence of B1 15 together with
TG, initiation codon; A, GATA box; the putative 5' leading sequence, TATA site, 3'-end poly(A)
B115). (B) CAT activity in CV1 cells. site, and protein sequence is shown (Fig. 6). The putative ORF
ned with 1 ,ug of the HIV LTR CAT B115 contains 42% basic amino acid residues. No classic
he data are representative of at least leucine zipper and zinc finger motifs were detected in B115.
Transactivation of the HIV-1 LTR by pSV-B115 is Spl site
dependent. To determine whether pSV-B115 required Spl
sites to transactivate the HIV LTR, CV1 cells were cotrans-
fected with pSV-B115 and either -83CAT or -29CAT into
r (data not shown). These results CV1 cells. B115 appears to function like pZVH14 in CV1 cells,
leotide which is capable of form- since it transactivated - 83CAT but not - 29CAT (Fig. 7A).
g sites may inhibit the ability of Similar experiments were performed with H9 cells (human T
HIV LTR. cells). Both pSV-B115 and pZVH14 transactivated -83CAT
t of ZVH14 possesses transacti- but not -29CAT (Fig. 7B). This finding demonstrated that
r identify and characterize the pSV-B115 is capable of transactivating the HIV-1 LTR in an
ansactivation of the HIV-1 LTR, Spl-dependent manner in CV1 and human T cells.
several deletions and truncation clones of the 8.7-kb ZVH14
insert were constructed and tested for the ability to transacti-
vate the HIV LTR. The transactivation level of each clone is
shown in Fig. 4. All clones (pZVH14-1, pZVH14-2,
pZVH14-3, pZVH14-4, pZVH14-8, and pZVH14-9) which
contain the 1-kb HincII-XbaI fragment were capable of trans-
activating the HIV LTR. Clones which contained the right-
hand 0.8-kb PstI-HindIII fragment were also able to consis-
tently transactivate the HIV LTR (fourfold). These studies
DISCUSSION
Studies regarding the role of HHV-6 or its gene segments in
regulating the expression of HIV-1 may be important to
understanding the pathogenesis of HIV-1, since HHV-6 is
considered an important cofactor of HIV-1. Activation of HIV
expression by human herpesviruses or viral genes involves
different regulatory elements of the HIV-1 promoter. Using
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FIG. 7. Transactivation of the HIV-1 LTR by pSV-BI15 in CV1 (A) and H9 (B) cells. The amount of pZVH14
cotransfections was 8 jig. The data are representative of five independent experiments.
cotransfection experiments of various HIV-1 LTR CAT con-
structs with HHV-6 (GS) gene segment pZVH14, we have
examined the function of individual known regulatory ele-
ments of the HIV-1 LTR in pZVH14-induced transactivation.
Our data indicated that pZVH14 transactivated the HIV-1
LTR through the Spi binding sites and that NF-KB sites are
not essential in transactivation. Another study has demon-
strated that NF-KB binding sites are necessary for transactiva-
tion of the HIV-1 LTR by another HHV-6 (GS) gene segment,
pZBV70 (11). Together, the data suggest that activation of the
HIV-1 LTR by HHV-6 involves at least two HHV-6 genes and
multiple response elements within the HIV promoter. A
similar phenomenon has been observed whereby both Spl and
NF-KB sites in the HIV LTR are required for transactivation
by HSV-l infection (30).
From this study, it is clear that efficient transactivation of the
HIV LTR by pZVH14 requires functional Spl binding sites.
Since an HIV LTR construct containing Spl binding sites I and
II (-1 17SP3) was efficiently transactivated by pZVH 14. In
contrast, the HIV LTR construct containing only Spl binding
site I showed poor activation, suggesting that pZVH14 re-
quires at least two tandem Spl binding sites to exert its optimal
function. Also, the triplex formation data in Fig. 3 suggest that
activation is Spl site specific, since NF-KB did not show
significant blocking function. The same triplex oligomer,
HIVSp, could also specifically block transcription of the HIV
LTR but did not form a triplex with regulatory regions of c-myc
and interleukin 2 receptor promoters as shown by McShan et
al. (28). The major trans-acting domain of pZVH14 is localized
to a small fragment which contains a 115-amino-acid ORF
(B115). It is likely that this 115-amino-acid ORF is responsible
for Spl-dependent transactivation.
There are several possible mechanisms by which Spl-depen-
dent transactivation may occur. First, the putative protein may
directly bind to Spl sites in a similar fashion as the cellular
transcription factor Spl. Second, it may act as a coactivator by
or pSV-B115 used in
directly or indirectly interacting with Sp I or its family members
(12, 24, 36), such as bovine papillomavirus E2 (24). Third, it
may interfere with the posttranslational modification of Spl,
such as phosphorylation. Finally, it may activate expression of
cellular genes which may be involved in transactivation, such as
tumor necrosis factor-induced Spl in micromuscular cells (16),
although expression of Spl family members, unlike that of
NF-KB or AP-1 family members, is relatively stable and usually
constitutive.
Sequence analyses indicate that there are one GATA box 30
bp and one TATA box 98 bp upstream of the first ATG codon
and a polyadenylation signal sequence (ATTAAA) at position
154 bp downstream of the putative ORF B115 (Fig. 6). The
HHV-6 Bi 15 is, therefore, likely to be expressed. The putative
protein consists of 115 amino acids, is highly basic, and is rich
in histidine. Sequence comparisons show that B1 15 does not
have sequence similarity with the cytomegalovirus AD 169
genome. No significant sequence homology has been detected
between B115 and human transcription factor Spi. Preliminary
experiments with B115, expressed in vitro in a wheat germ
transcription-translation system, found the protein to have a
molecular mass of 18 kDa as expected. Using a 139-bp
AvaI-PvuII fragment of the HIV-1 LTR (containing NF-KB,
Spl, and TATA sites) as a probe, no binding of the in
vitro-translated B115 was detected in gel shift assays, while
purified Spl protein showed a band shift (data not shown).
Furthermore, no additional band shift was detected when B 1 15
and Spl proteins were added together. These data suggest that
B115 does not bind to Spl sites or to Spl protein. Whether
B1 15 acts through another cellular factor to interact with Spl
motifs remains to be elucidated.
Current studies are in progress to further identify and
characterize the protein encoded by B1 15. Since pZVH14 also
has oncogenic potential and has been detected in human
-83CAT
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+
_
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lymphoma (22), studies to localize the transforming activity in
this segment are also in progress.
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